Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 2—February 2024
Letter

No Evidence for Clade I Monkeypox Virus Circulation, Belgium

Cite This Article

To the Editor: As professionals involved in the mpox response in Belgium, we read with concern the report by Kibungu et al. on a clade I mpox outbreak linked to sexual transmission in the Democratic Republic of the Congo (DRC), in March 2023 (1). The authors and the World Health Organization (WHO) reported that the male index case had a sexual encounter with another man in Belgium before traveling to the DRC, where he developed symptoms the day he arrived and tested positive for monkeypox virus (MPXV) 8 days later (2). By that timeline, WHO suggested, the man likely was infected in Belgium. This conclusion raised concerns about clade I MPXV circulation within sexual networks in Belgium and Europe, regions highly affected by the 2022 clade IIb outbreak.

Mpox diagnoses in Belgium were mostly made by using a PCR that does not distinguish between clades (3). After the aforementioned reports, we retested stored samples from 296 mpox patients, 37% of all mpox patients in Belgium, by using a clade I–specific PCR (4). None tested positive.

In addition, from October 2022 onward, few mpox cases were reported in Belgium; none occurred in the 6 weeks before the DRC cluster started. Also, in the 9 months after the DRC outbreak, only 4 mpox cases were detected in Belgium, the earliest of which was diagnosed 12 weeks after the DRC index case (L. Liesenborghs et al., unpub. data). Moreover, during January–November 2023, we screened 2,415 men visiting our sexual health clinic using an MPXV-specific PCR as part of ongoing surveillance to detect undiagnosed or asymptomatic infections (5). We detected only 1 presymptomatic clade IIb MPXV infection.

On the basis of this information, we have no indications that clade I MPXV has been circulating in Belgium. However, sustained vigilance, clade differentiation, and timely outbreak investigations remain crucial to halting potential spread of clade I MPXV through sexual transmission.

Top

Acknowledgment

This project was funded in part by the Research Foundation Flanders (grant no. G096222N to L.L.); C.V.D. is a fellow of the Research Foundation Flanders (grant no. 12B1M24N).

Top

Laurens Liesenborghs1Comments to Author , Jasmine Coppens1, Christophe Van Dijck, Isabel Brosius, Irith De Baetselier, Koen Vercauteren2, and Marjan Van Esbroeck2
Author affiliations: Institute of Tropical Medicine, Antwerp, Belgium (L. Liesenborghs, J. Coppens, C. Van Dijck, I. Brosius, I. De Baetselier, K. Vercauteren, M. Van Esbroeck); Katholieke Universiteit Leuven, Leuven, Belgium (L. Liesenborghs, C. Van Dijck)

Top

References

  1. Kibungu  EM, Vakaniaki  EH, Kinganda-Lusamaki  E, Kalonji-Mukendi  T, Pukuta  E, Hoff  NA, et al.; International Mpox Research Consortium. Clade I–associated mpox cases associated with sexual contact, the Democratic Republic of the Congo. Emerg Infect Dis. 2024;30:1726. DOIPubMedGoogle Scholar
  2. World Health Organization. Mpox (monkeypox)—Democratic Republic of the Congo [cited 2023 Dec 21]. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON493
  3. Coppens  J, Vanroye  F, Brosius  I, Liesenborghs  L, van Henten  S, Vanbaelen  T, et al.; ITM MPX study group. Alternative sampling specimens for the molecular detection of mpox (formerly monkeypox) virus. J Clin Virol. 2023;159:105372. DOIPubMedGoogle Scholar
  4. Li  Y, Zhao  H, Wilkins  K, Hughes  C, Damon  IK. Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods. 2010;169:2237. DOIPubMedGoogle Scholar
  5. Van Dijck  C, De Baetselier  I, Kenyon  C, Liesenborghs  L, Vercauteren  K, Van Esbroeck  M, et al.; ITM Monkeypox Study Group. Mpox screening in high-risk populations finds no asymptomatic cases. Lancet Microbe. 2023;4:e1323. DOIPubMedGoogle Scholar

Top

Cite This Article

DOI: 10.3201/eid3002.231746

Original Publication Date: January 08, 2024

1These first authors contributed equally to this article.

2These last authors contributed equally to this article.

Related Links

Top

Table of Contents – Volume 30, Number 2—February 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Laurens Liesenborghs, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium

Send To

10000 character(s) remaining.

Top

Page created: December 31, 2023
Page updated: January 24, 2024
Page reviewed: January 24, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external